en · de · es · fr · pt
dihexa-notes.peptides4800.com › Guide › Overview And Research Status — Reference Sheet

Overview And Research Status — Reference Sheet

By Editorial Desk · published 2026-05-14 · last reviewed 2026-06-06 · Guide

This is a working overview of angiotensin IV, written for readers who want more than a one-paragraph summary but less than a textbook.

This page was last updated on 2026-06-06 and is reviewed periodically as new material appears.

Overview and Research Status

Development of dihexa has been linked to academic research on synaptogenesis, the formation of new synapses. Preclinical studies in rodents have examined its effects on learning and memory tasks. These studies are often cited in discussions about cognitive enhancement, but they do not establish safety or efficacy in humans. The compound's patent and commercial history is limited, and it is not widely available through pharmaceutical channels. Most information comes from animal models and in vitro experiments. Researchers continue to explore its basic biology rather than clinical applications.

Dihexa is not approved for human use in the United States or the European Union. It is commonly sold as a research chemical, a category that may not require the same regulatory review as medicines. Buyers should note that product labels may lack independent verification of identity or purity. The legal status can vary by country, and importation may be restricted. Reliable information about sourcing and quality is often scarce. Scientific publications typically use synthesized material from laboratories rather than commercial consumer products.

Dihexa is a synthetic peptide studied in laboratory research. It is often described as an angiotensin IV analog or a hepatocyte growth factor mimetic. The compound emerged from investigations into angiotensin IV and its effects on neural pathways. It is not an approved medication, and controlled human trials are lacking. In literature and online forums, it is discussed mainly as a research chemical. Its chemical name appears as N-hexanoic-Tyr-Ile-(6-aminohexanoic amide) in some sources.

Chemical Identity and Research Background

The proposed mechanism involves interaction with the hepatocyte growth factor (HGF) system and its receptor, c-Met. Dihexa is described in some studies as an HGF mimetic, meaning it may mimic or enhance HGF-mediated signaling. Activation of c-Met can influence cell growth, survival, and cytoskeletal remodeling, pathways that intersect with synaptic plasticity. However, the precise binding targets and downstream events for dihexa are not fully established, and alternative mechanisms have been suggested.

Dihexa is a synthetic peptide with the chemical name N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide, and it is structurally related to angiotensin IV, a naturally occurring peptide fragment. Researchers developed it as a modified analog intended to alter stability and activity relative to the parent peptide. Its short sequence and fatty acid chain distinguish it from many endogenous peptides, and published studies often describe it under the abbreviation dihexa. The compound is classified as a laboratory compound rather than an approved therapeutic in most jurisdictions.

Dihexa at a glance

PropertyValueNotes
CAS Registry Number1401708-83-5Identifier used in chemical databases.
Common synonymsP21; N-hexanoic-Tyr-Ile-(6-aminohexanoic amide)Names vary by supplier and publication.
Physical formWhite to off-white powderLyophilized solid typical of peptides.
SolubilitySoluble in DMSO; limited in waterAqueous preparation may need a co-solvent.
Storage-20 °C, desiccated, protected from lightReduce freeze-thaw cycles to maintain stability.

Proposed Mechanism And Evidence Gaps

Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.

Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.

Related pages on this site

Handling and Quality Verification

Quality control usually combines reverse-phase high-performance liquid chromatography with mass spectrometry. Chromatography estimates purity and detects related impurities, while mass spectrometry supports molecular identity. Nuclear magnetic resonance can provide additional structural confirmation when needed. Stability data for dihexa are limited, and degradation pathways may depend on pH, temperature, and moisture. Open questions include long-term stability in different formulations and the effect of repeated freeze-thaw cycles on measured purity. Such tests help confirm that a batch matches its label before use.

In laboratory settings, dihexa is typically handled as a lyophilized peptide powder. Appropriate personal protective equipment and a ventilated workspace are standard practices for weighing and transferring research chemicals. Because the compound lacks regulatory approval for clinical use, it should not be given to people. Institutional safety rules and local regulations govern its acquisition, storage, and disposal. Suppliers often provide a certificate of analysis that lists purity, identity, and batch-specific handling notes.

Identity And Regulatory Status

Regulatory treatment varies by country. Dihexa does not appear in major pharmacopeias as a licensed therapeutic substance. Suppliers may use labels such as research use only or not for human consumption. Such labels reflect legal and quality-control boundaries rather than evidence of clinical benefit. Importation, possession, and sale can be restricted depending on local laws, and enforcement focuses on claims, distribution channels, and product categories. These rules can change, and they differ from rules for approved medicines.

Dihexa is a synthetic peptide studied in preclinical neuroscience. It is often described as an angiotensin IV analog or derivative. The compound also appears under research codes such as PNB-0408 and N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide. It is not an approved drug, and it is not a conventional vitamin or nutrient. In many jurisdictions, material sold as dihexa is handled as a research chemical rather than a medicine or supplement. This classification affects how the material is labeled and distributed.

Preclinical Research and Regulation

Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.

Most published reports on dihexa come from cell cultures and animal models. Studies have examined markers of synapse formation, dendritic spine density, and performance on learning tasks in rodents. Proposed mechanisms center on hepatocyte growth factor and its c-Met receptor, with additional attention to angiotensin IV-related pathways. These findings are experimental and have not been confirmed as clinical benefits in humans. The literature often uses different tasks and endpoints, which complicates direct comparison across studies.

Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.

Background from the literature

== Function == Erythroferrone is a hormone that regulates iron metabolism through its actions on hepcidin. As shown in mice and humans, it is produced in erythroblasts, which proliferate when new red cells are synthesized, such as after hemorrhage when more iron is needed (so-called stress erythropoiesis). This process is governed by the renal hormone, erythropoietin. Its mechanism of action is to inhibit the expression of the liver hormone, hepcidin. This process is governed by the renal hormone, erythropoietin. By suppressing hepcidin, ERFE increases the function of the cellular iron export channel, ferroportin. This then results in increased iron absorption from the intestine and mobilization of iron from stores, which can then be used in the synthesis of hemoglobin in new red blood cells. Erythroferrone inhibits hepcidin synthesis by binding bone morphogenetic proteins and thereby inhibiting the bone morphogenetic protein pathway that controls hepcidin expression. Mice deficient in the gene encoding erythroferrone have transient maturational hemoglobin deficits and impaired hepcidin suppression in response to phlebotomy with a delayed recovery from anemia. In its role as myonectin, it also promotes lipid uptake into adipocytes and hepatocytes.

==== Cannabinoids ==== According to a study published in the August 15, 2004 issue of the journal Cancer Research, cannabinoids, the active ingredients in marijuana, restrict the sprouting of blood vessels to gliomas (brain tumors) implanted under the skin of mice, by inhibiting the expression of genes needed for the production of vascular endothelial growth factor (VEGF).

=== 2013–2014: First regulatory actions === In March 2013, the US Financial Crimes Enforcement Network (FinCEN) established regulatory guidelines for "decentralized virtual currencies" such as bitcoin, classifying American bitcoin miners who sell their generated bitcoins as money services businesses, subject to registration and other legal obligations. In May 2013, US authorities seized the unregistered exchange Mt. Gox. In June 2013, the US Drug Enforcement Administration seized ₿11.02 from an individual attempting to use them to purchase illicit drugs. This marked the first time a government agency had seized bitcoins. The FBI seized about ₿30,000 in October 2013 from Silk Road, following the arrest of its founder Ross Ulbricht. In December 2013, the People's Bank of China prohibited Chinese financial institutions from using bitcoin. After the announcement, the value of bitcoin dropped, and Baidu no longer accepted bitcoins for certain services. Buying real-world goods with any virtual currency had been illegal in China since at least 2009.

More zeroes may be added in a process called zero filling to improve the appearance of the final spectrum although there is no improvement in resolution. Alternatively, interpolation after the Fourier transform gives a similar result.

While AM could be an important biomarker for bacterial infections like sepsis, AM has diminished value in its utility for cardiovascular diseases (CVD), attributable to its minimal increase in these conditions and reduced half-life. AM is associated with controlling vascular integrity, blood pressure, and general cardiovascular function. Since AM has been noted for its exacerbated levels in intense diseases with an elevated concern for mortality, AM could still have some value as a predictive biomarker of harmful clinical consequences for an array of cardiovascular illnesses. AM has conservatory effects against arteriosclerosis and vascular harm. Extended AM administration or hyper-expression of its target gene in rodent model organisms diminishes vascular hyperplasia, fatty streak construction, and intimal expansion. AM also has angiogenic characteristics, leading to organ and tissue maintenance by reducing the risk of ischemic diseases. AM binds to particular receptors like calcitonin gene-related peptide (CGRP) receptors, which affects the cardiovascular system by contributing to vasodilation as well as elevated heart rate and blood pressure.

Sources: en.wikipedia.org

Reference notes

In molecular biology, Enhancer of rudimentary homolog is a protein that in humans is encoded by the ERH gene. The Drosophila protein enhancer of rudimentary protein is a small protein of 104 amino acids. It has been found to be an enhancer of the rudimentary gene, involved in pyrimidine biosynthesis. From an evolutionary point of view, enhancer of rudimentary is highly conserved and has been found to exist in probably all multicellular eukaryotic organisms. It has been proposed that this protein plays a role in the cell cycle. PDBe-KB provides an overview of all the structure information available in the PDB for Human Enhancer of rudimentary homolog (ERH) PDBe-KB provides an overview of all the structure information available in the PDB for Mouse Enhancer of rudimentary homolog (ERH)

German chemists Walter Noddack, Otto Berg, and Ida Tacke reported the discovery of element 75 and element 43 in 1925, and named element 43 masurium (after Masuria in eastern Prussia, now in Poland, the region where Walter Noddack's family originated). This name caused significant resentment in the scientific community, because it was interpreted as referring to a series of victories of the German army over the Russian army in the Masuria region during World War I; as the Noddacks remained in their academic positions while the Nazis were in power, suspicions and hostility against their claim for discovering element 43 continued. The group bombarded columbite with a beam of electrons and deduced element 43 was present by examining X-ray emission spectrograms. The wavelength of the X-rays produced is related to the atomic number by a formula derived by Henry Moseley in 1913. The team claimed to detect a faint X-ray signal at a wavelength produced by element 43. Later experimenters could not replicate the discovery, and it was dismissed as an error. Still, in 1933, a series of articles on the discovery of elements quoted the name masurium for element 43. Some more recent attempts have been made to rehabilitate the Noddacks' claims, but they are disproved by Paul Kuroda's study on the amount of technetium that could have been present in the ores they studied: it could not have exceeded 3 × 10−11 μg/kg of ore, and thus would have been undetectable by the Noddacks' methods.

== Physical properties == The boiling points of the pentane isomers range from about 9 to 36 °C. As is the case for other alkanes, the more thickly branched isomers tend to have lower boiling points. The same tends to be true for the melting points of alkane isomers, and that of isopentane is 30 °C lower than that of n-pentane. However, the melting point of neopentane, the most heavily branched of the three, is 100 °C higher than that of isopentane. The anomalously high melting point of neopentane has been attributed to the tetrahedral molecules packing more closely in solid form; this explanation is contradicted by the fact that neopentane has a lower density than the other two isomers, and the high melting point is actually caused by neopentane's significantly lower entropy of fusion. The branched isomers are more stable (have lower heat of formation and heat of combustion) than n-pentane. The difference is 1.8 kcal/mol for isopentane, and 5 kcal/mol for neopentane. Rotation about two central single C-C bonds of n-pentane produces four different conformations.

The stadium's name, Oakwell, originates from the well and oak tree that were on the site when first built. Oakwell is a multi-purpose sports development in Barnsley, South Yorkshire, used primarily by the club for playing its home fixtures, and its reserves. While the name 'Oakwell' generally refers to the main stadium, it also includes several neighbouring venues which form the facilities of the Barnsley academy – an indoor training pitch, a smaller stadium with seating on the south and west sides for around 2,200 spectators, and several training pitches used by the different Barnsley squads. Until 2003, the stadium and the vast amount of land that surrounds it was owned by Barnsley themselves; however, after falling into administration in 2002 the council purchased the main Oakwell Stadium to allow the club to pay its creditors and remain participants in the Football League. The stadium's capacity is 23,287.

Sources: en.wikipedia.org

Reference notes

Polymer-based nanoparticles can be made from either natural or synthetic sources. Nanospheres and nanocapsules are polymeric nanoparticle systems. Natural polymers can be found in the environment or human body. On the other hand, synthetic polymers do not occur naturally and are artificially developed polymers with chemical modifications. Natural polymer-based nanoparticles can be made up of chitosan, hyaluronic acid, alginate, and gelatin. Natural polymers exhibit excellent biocompatibility and biodegradability, and low toxicity. Synthetic polymer-based nanoparticles can consist of polyglycolic acid (PGA), poly (lactic acid) (PLA), and poly(lactide-co-glycolide) (PLGA). A study evaluated chitosan nanoparticles loaded with an anti-epileptic drug, phenytoin (PHT), to treat epilepsy. Observations suggested high stability, sustained release, and bioavailability when these particles where administered via the intranasal route. Similarly, administering PLGA nanoparticles loaded lamotrigine (LTG), polymer-based nanoparticle, showed better permeation through BBB and higher bioavailability.

=== Comparative Experiments === A comparative NAIL-MS experiment is quite similar to a SILAC experiment but for RNA instead of proteins. First, two populations of the respective cells are cultivated. One of the cell populations is fed with growth medium containing unlabeled nutrients, whereas the second population is fed with growth medium containing stable isotope labeled nutrients. The cells then incorporate the respective isotopologues into their RNA molecules. One of the cell populations serves as a control group whereas the other is subject to the associated research (e.g. KO strain, stress). Upon harvesting of the two cell populations they are mixed and co-processed together to exclude purification-bias. Due to the distinct masses of incorporated nutrients into the nucleosides a differentiation of the two cell populations is possible by mass spectrometry.

==== United Arab Emirates ==== The UAE has been a center for political oriented think tanks which concentrate on both regional and global policy. Notable think tank have emerged in the global debate on terrorism, education & economical policies in the MENA region. Think tanks include:

The requirement of arginine in the urea cycle is reduced, as dogs have a functional pyrroline-5-carboxylate synthase. Dogs have a functional delta 6 desaturase, hence no specific need for arachidonic acid. Dogs have a functional sulfinoalanine decarboxylase and can synthesise taurine from methionine and cysteine; however, some breeds have a genetic predisposition to taurine deficiency. Taurine supplementation is recommended for dogs at risk of taurine deficiency and dogs with dilated cardiomyopathy. Unlike cats, dogs and humans can use Vitamin D2 nearly as efficiently as they use Vitamin D3.

=== New York Mets (1962), later career, retirement === With New York, Mizell was used mainly out of the bullpen. His second appearance with the team (on May 15) was a start, though, in which he allowed four runs (three earned) in six innings against the Cubs. Though he got a no decision, the Mets won 6–5. Against the expansion Houston Colt .45's on June 14, he pitched "rather well" according to sportswriter Louis Effrat, throwing six scoreless innings after starter Jay Hook was unable to record an out in a 10–2 defeat. He failed to win a game with the Mets, however, posting a 7.34 ERA in 17 games (two starts) before getting released on August 4. In his last appearance with New York, on July 25, he had allowed six runs in 2+1⁄3 innings in an 11–5 loss to Milwaukee. After getting cut by the Mets, Mizell was reacquired by the Pirates. This time, however, he would pitch for the Columbus Jets of the Class AAA International League, and he would have to serve as an instructor until space for him became available on the team's roster. He ultimately made four appearances (three starts) for Columbus, posting a 2–1 record and a 3.27 ERA. Pittsburgh did not recall him after the season. Mizell participated in the Arizona Instructional League following the 1962 season, but when no teams signed him in 1963, he retired.

Sources: en.wikipedia.org

Frequently asked questions

What is dihexa?

Dihexa is a synthetic peptide investigated in preclinical research. It is often classified as an angiotensin IV analog or an HGF mimetic. It is not an approved medicine.

Is dihexa approved for human use?

No. Regulatory agencies have not approved dihexa for human use. It is sold as a research chemical in some markets, and human safety and efficacy data are lacking.

What is dihexa studied for?

Laboratory studies have examined its effects on synapse formation and cognitive tasks in animals. These are early-stage findings. They do not prove benefits or safety in people.

What is dihexa?

Dihexa is a synthetic peptide analog of angiotensin IV, often described as an HGF mimetic in research literature. It is studied for effects on synaptic connectivity in laboratory models. It is not an approved medication.

Network